MX2012002830A - Formulacion estable de hialuronano/esteroide. - Google Patents

Formulacion estable de hialuronano/esteroide.

Info

Publication number
MX2012002830A
MX2012002830A MX2012002830A MX2012002830A MX2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A
Authority
MX
Mexico
Prior art keywords
stable
composition
steroid formulation
stable hyaluronan
hyaluronan
Prior art date
Application number
MX2012002830A
Other languages
English (en)
Spanish (es)
Inventor
Grace Chang
Elizabeth Voschin
Li-Ping Yu
Eugene Skrabut
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2012002830A publication Critical patent/MX2012002830A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2012002830A 2009-09-10 2010-08-10 Formulacion estable de hialuronano/esteroide. MX2012002830A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/556,869 US8273725B2 (en) 2009-09-10 2009-09-10 Stable hyaluronan/steroid formulation
PCT/US2010/044975 WO2011031402A1 (en) 2009-09-10 2010-08-10 Stable hyaluronan/steroid formulation

Publications (1)

Publication Number Publication Date
MX2012002830A true MX2012002830A (es) 2012-04-10

Family

ID=43648224

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002830A MX2012002830A (es) 2009-09-10 2010-08-10 Formulacion estable de hialuronano/esteroide.

Country Status (8)

Country Link
US (2) US8273725B2 (cg-RX-API-DMAC7.html)
EP (2) EP3622820A1 (cg-RX-API-DMAC7.html)
JP (2) JP6121717B2 (cg-RX-API-DMAC7.html)
CN (1) CN102573468B (cg-RX-API-DMAC7.html)
AR (1) AR078281A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012005423B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012002830A (cg-RX-API-DMAC7.html)
WO (1) WO2011031402A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2633978A1 (en) 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects
MX2012001204A (es) 2009-07-30 2012-08-03 Carbylan Biosurgery Inc Composiciones de polimero de acido hialuronico modificado y metodos relacionados.
CN103732264B (zh) 2011-04-20 2017-07-14 卡比兰治疗公司 原位凝胶形成组合物
TWI424007B (zh) 2011-12-22 2014-01-21 Ind Tech Res Inst 使膠體交聯的方法與藉由此方法形成之經交聯的膠體
WO2014110454A1 (en) * 2013-01-11 2014-07-17 Carbylan Biosurgery, Inc. Stabilized compositions comprising hyaluronic acid
IT201600075246A1 (it) 2016-07-19 2018-01-19 Jointherapeutics S R L Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
CN106983733A (zh) * 2017-03-08 2017-07-28 江苏富泽药业有限公司 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用
KR20190038368A (ko) 2017-09-29 2019-04-08 주식회사 엘지화학 히알루론산 기반 하이드로겔 약제학적 안정화 조성물 및 그 제조방법
CN118021719A (zh) * 2022-11-11 2024-05-14 北京华视诺维医疗科技有限公司 一种曲安奈德组合物及其制备方法
WO2025068242A1 (en) * 2023-09-25 2025-04-03 Hyamedix Dexamethasone delivery system

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
SE442820B (sv) 1984-06-08 1986-02-03 Pharmacia Ab Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
SE8501022L (sv) 1985-03-01 1986-09-02 Pharmacia Ab Format alster och forfarande for dess framstellning
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US4866050A (en) * 1988-04-27 1989-09-12 Ben Amoz Daniel Ultrasonic transdermal application of steroid compositions
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5356883A (en) * 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5143724A (en) 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US5207983A (en) * 1992-01-29 1993-05-04 Sterling Winthrop Inc. Method of terminal steam sterilization
IT1260154B (it) * 1992-07-03 1996-03-28 Lanfranco Callegaro Acido ialuronico e suoi derivati in polimeri interpenetranti (ipn)
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US5621093A (en) * 1995-06-06 1997-04-15 Anika Research, Inc. Steam-sterilizing solid hyaluronic acid
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
TW577758B (en) * 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
US6521223B1 (en) * 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2002009792A1 (en) 2000-07-28 2002-02-07 Anika Therapeutics, Inc. Bioabsorbable composites of derivatized hyaluronic acid
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DK1337279T3 (da) * 2000-11-24 2006-09-25 Breath Ltd Sterilisation af glucocorticosteroidsuspensioner
WO2003002159A1 (en) * 2001-06-29 2003-01-09 Biovitrum Ab Process for bulk autoclaving
AU2003230948A1 (en) 2002-04-17 2003-11-03 Genzyme Corporation Cross-linked hyaluronate compounds
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050142152A1 (en) 2003-12-30 2005-06-30 Leshchiner Adelya K. Polymeric materials, their preparation and use
EP2754454A3 (en) 2004-01-07 2014-09-24 Seikagaku Corporation Non-steroidal anti-inflammatory drug derivatives
US20060094700A1 (en) * 2004-11-02 2006-05-04 Allergan, Inc. Heat sterilization of a steroid in the presence of phosphate
CA2633957A1 (en) 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
WO2008098019A2 (en) * 2007-02-05 2008-08-14 Carbylan Biosurgery, Inc. Polymer formulations for delivery of bioactive agents
FR2918276B1 (fr) 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
JP2011510971A (ja) 2008-01-31 2011-04-07 ソフラディム・プロデュクスィヨン 中性pHで可溶性の終末的に滅菌されたコラーゲンの製造

Also Published As

Publication number Publication date
US20110059918A1 (en) 2011-03-10
US8680073B2 (en) 2014-03-25
WO2011031402A1 (en) 2011-03-17
US20120316131A1 (en) 2012-12-13
CN102573468B (zh) 2015-05-20
US8273725B2 (en) 2012-09-25
AR078281A1 (es) 2011-10-26
JP6121717B2 (ja) 2017-04-26
EP2475251B1 (en) 2019-07-17
EP3622820A1 (en) 2020-03-18
BR112012005423A2 (pt) 2017-07-04
JP2015172095A (ja) 2015-10-01
EP2475251A1 (en) 2012-07-18
BR112012005423B1 (pt) 2022-09-13
CN102573468A (zh) 2012-07-11
JP2013504570A (ja) 2013-02-07
EP2475251A4 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
MX2012002830A (es) Formulacion estable de hialuronano/esteroide.
IN2012DN01216A (cg-RX-API-DMAC7.html)
BR112012017136A2 (pt) Composição farmacêutica compreendendo 3-beta- hidróxi-5-alfa-pregnan-20-ona com propriedades de armazenamento e solubidade aperfeiçoadas.
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
SG10201901089TA (en) Novel lipids and compositions for the delivery of therapeutics
BR112014015940A2 (pt) composição de novo fármaco de carboidrato para tratamento de doenças humanas
PH12012502016A1 (en) Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
TN2011000471A1 (en) Pharmaceutical composition presenting anti-inflammatory properties
UA105503C2 (uk) Похідні 1-аміно-2-циклобутилетилборонової кислоти
BR122020001787A8 (pt) Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
BR112012033391A2 (pt) kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenova.
MX349070B (es) Preparacion y/o formulacion de proteinas reticuladas con polisacaridos.
BR112014016550A2 (pt) formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
BR112015021112A2 (pt) composições farmacêuticas que compreendem everolimo
BR112014032239A2 (pt) inibidores da família de mir-15 de micro-rnas
MY174090A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2012007229A (es) Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos.
BR112014016661A2 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
BR112017011476A2 (pt) composição baseada em aminoácidos para recuperação de fibroelastina em tecidos conjuntivos dérmicos e uso
PL4247335T3 (pl) Kompozycja farmaceutyczna zawierająca kannabidiol i kwas hialuronowy
UA105920C2 (uk) ПОХІДНІ СПОЛУК СТЕРОЇДАЛ[3,2-с]ПІРАЗОЛУ З ГЛЮКОКОРТИКОЇДНОЮ АКТИВНІСТЮ
EP2145623A4 (en) PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR ACCELERATING THE PROCESS OF WOUND HEALING AND OTHER SURFACE INJURIES
WO2009120700A3 (en) Inhibition of dcps
MX2013000729A (es) Composiciones ciclopolisacárido anionico-catiónico y bendamustina.

Legal Events

Date Code Title Description
FG Grant or registration